# Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Source: https://onco.cc/trials/nct07125872/  
OnCo record `nct07125872` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of CD19 t-haNK in non-Hodgkin lymphoma, run by ImmunityBio, Inc., now recruiting.

## Summary

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma is a phase 2 interventional study registered as NCT07125872 by ImmunityBio, Inc., with 20 participants planned, started 2025-11-11 and due to reach its primary completion in 2027-05-25. Interventions recorded: CD19 t-haNK- IV Administration.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07125872
- Phase: 2
- Setting: Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
- Sponsor: ImmunityBio, Inc.
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07125872: https://clinicaltrials.gov/study/NCT07125872

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [CD19 t-haNK](https://onco.cc/drugs/cd19-t-hank/)
- companies: [ImmunityBio](https://onco.cc/companies/immunitybio/)

---
JSON: https://onco.cc/api/v1/entities/nct07125872.json